Epoxyeicosatrienoic acids: a double-edged sword in cardiovascular diseases and cancer.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 22182836.
- Also identified by DOI 10.1172/JCI61453 and PMC identifier 3248310.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Epoxyeicosatrienoic acids (EETs) generated from arachidonic acid by cytochrome P450 (CYP) epoxygenases have beneficial effects in certain cardiovascular and kidney diseases. Hence, great efforts have been made to develop drugs targeting the EET pathway. Some of these agents are currently under evaluation in clinical trials for treatment of hypertension and diabetes. In this issue of the JCI, Panigrahy et al. evaluate in a systematic way the role of CYP epoxygenases and the metabolites they generate in cancer progression. Their findings, along with previous studies, raise concerns about using these drugs in humans.
Medical subject headings
- Eicosanoids
- Neoplasm Metastasis
- Neoplasms, Experimental